The relationship of PSA, PSAD and clinicopathological stage in patients with prostate cancer

Nong, Shaojun; Di, Wen; Fan, Caibin

doi:10.1007/s11805-007-0318-y

Cited by 1 publication

(2 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the ROC, area under the curve (AUC) of PSAD (0.75) showed higher compared to PSA (0.65). PSAD more than 0.15 ng/mL/cm 3 shown sensitivity 93% and specificity 38% compared to PSA more than 20 g/ mL which shown sensitivity 82 % and specificity 21% (FIGURE 1). Positive predictive value (PPV) of PSA in predictive bone metastases in this study was 93.33 (78.02-98.22%) and negative predictive value (NPV) was 34.15 (30.16-38.37%).…”

Section: Site Of Bone Metastasismentioning

confidence: 98%

See 1 more Smart Citation

Diagnosis value of prostate specific antigen density (PSAD) and prostate specific antigen (PSA) in bone metastases of prostate cancer among Indonesian population

et al. 2020

View full text Add to dashboard Cite

Cancer prostate (PCa) is currently reported as the most diagnosed cancer in males. Bone metastases in PCa indicate poor prognosis and the major cause of pain and death. Early diagnosis of metastases is important in PCa management. Prostate specific antigen (PSA) velocity was used to predict overall survival and metastasis-free survival. However, this test should be conducted 2 times, for at least 4 weeks apart. Therefore, a cross-sectional test with higher positive probability value is needed. This study aimed to compare PSA density (PSAD) and PSA level to evaluate patients at risk of bone metastases in Yogyakarta, Indonesia. Aretrospective study with a total subject of 106 patients with (n = 31) and without (n = 75) bone metastases were analyzed. The initial PSA measurement, as well as bone scan and prostate volume, were evaluated in all patients. Bone survey found to be positive in 31/106 (29.2%) patients. The total of 50(47.2%), 10(9.4%) and 46(43.4%) patients had PSA level <50, 50-100 and >100ng/mL, respectively. Furthermore, receiver operating characteristic (ROC) area under the curve of PSAD (0.75) was higher that that ofPSA (0.65).PSAD more than 0.15 indicated sensitivity of 93% and specificity of 38%, while PSA more than 20 ng/mL shown sensitivity 82% and specificity 21%. In conclusion, PSAD level more than 0.15 shows high sensitivity and specificity in causing potential skeletal metastases. Using this PSAD cut-off value, unnecessary investigation canbe avoided.

show abstract

Section: Site Of Bone Metastasismentioning

confidence: 98%

“…However, its role in predicting the bone metastatic needs to be evaluated. 3 Thus, this study as aimed to determine the role of PSAD compared to PSA in predicting bone metastatic in PCa.…”

Section: Introductionmentioning

confidence: 99%